Loading...
Market
Which therapy will achieve $1 billion in sales first by December 31, 2025?
2
Resolution / Starting Odds
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Company financial reports and market analysis
Story
FDA Approves Afami-cel for Synovial Sarcoma, Advances Cosibelimab and Adagrasib-Cetuximab Therapies
Aug 12, 2024, 11:03 AM
The FDA has granted accelerated approval to afami-cel, an engineered T cell therapy, for the treatment of adults with synovial sarcoma. This marks a significant advancement in immunotherapy for solid tumors. Additionally, the FDA has accepted the Biologics License Application (BLA) for cosibelimab, a treatment for locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC), following a resubmission to address previous deficiencies. Furthermore, the FDA has also granted accelerated approval to the combination of adagrasib and cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer.
View original story
Similar markets
BEAM-101 leads • 33%
Reni-cel leads • 33%
Casgevy leads • 33%
Yes • 33%
No • 34%
Top 3 but not best-selling • 33%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Yes • 50%
No • 50%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Aucatzyl (Autolus Therapeutics) • 25%
Kymriah (Novartis) • 25%
Yescarta (Gilead) • 25%
Other • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%